Minerva Neurosciences Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Remy Luthringer

Geschäftsführender

US$1.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	34.0%
Amtszeit als Geschäftsführer	10yrs
Eigentum des Geschäftsführers	2.6%
Durchschnittliche Amtszeit des Managements	8.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.5yrs

Jüngste Management Updates

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18

Minerva Neurosciences EPS beats by $0.03

Nov 02

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Remy Luthringer im Vergleich zu den Einnahmen von Minerva Neurosciences verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$34m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$2m	US$624k	-US$30m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$1m	US$600k	-US$32m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$51m
Dec 31 2021	US$1m	US$585k	-US$50m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	US$5m
Dec 31 2020	US$2m	US$565k	US$2m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$69m
Dec 31 2019	US$1m	US$543k	-US$72m
Sep 30 2019	n/a	n/a	-US$55m
Jun 30 2019	n/a	n/a	-US$54m
Mar 31 2019	n/a	n/a	-US$54m
Dec 31 2018	US$4m	US$525k	-US$50m
Sep 30 2018	n/a	n/a	-US$37m
Jun 30 2018	n/a	n/a	-US$36m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$2m	US$445k	-US$32m

Vergütung im Vergleich zum Markt: RemyDie Gesamtvergütung ($USD1.84M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD647.72K).

Entschädigung vs. Einkommen: RemyDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Remy Luthringer (63 yo)

10yrs

Amtszeit

US$1,835,160

Vergütung

Dr. Remy Luthringer, Ph D., serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Vent...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Remy Luthringer	Executive Chairman & CEO	10yrs	US$1.84m	2.64% $ 401.1k
Geoffrey Race	President	3.1yrs	US$1.40m	0.73% $ 111.4k
Frederick Ahlholm	Senior VP	3.1yrs	US$965.12k	0.25% $ 38.0k
Joseph Reilly	Senior VP & COO	10.3yrs	US$1.49m	keine Daten
William Boni	Vice President of Investor Relations & Corporate Communications	9.3yrs	keine Daten	keine Daten
Michael Davidson	Chief Medical Officer	7.9yrs	US$657.47k	keine Daten

8.6yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrenes Management: NERVDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.6 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Remy Luthringer	Executive Chairman & CEO	10yrs	US$1.84m	2.64% $ 401.1k
G. van Heek	Independent Director	10.3yrs	US$120.75k	0.036% $ 5.5k
Hans Hasler	Independent Director	6.9yrs	US$127.00k	0.018% $ 2.7k
David Kupfer	Lead Independent Director	9yrs	US$125.25k	0.34% $ 51.9k
Fouzia Laghrissi-Thode	Independent Director	9.5yrs	US$122.25k	0% $ 0

9.5yrs

Durchschnittliche Betriebszugehörigkeit

68yo

Durchschnittliches Alter

Erfahrener Vorstand: NERVDie Vorstandsmitglieder gelten als erfahren (9.5 Jahre durchschnittliche Amtszeit).

Minerva Neurosciences Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Insufficient new directors

Recent updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences Receives Second Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5550(b)(2)

Minerva Neurosciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement Nasdaq's Listing Rule 5550(b)(2)

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding from Frazier Healthcare Partners, Boehringer Ingelheim International GmbH

Nasdaq Determines to Delist Minerva Neurosciences' Securities from The Nasdaq Capital Market

Minerva Neurosciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Minerva Neurosciences, Inc. Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Receives Non-Compliance Notice from The Nasdaq Stock Market LLC

Minerva Neurosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences: Biotech On The Move

Minerva Neurosciences, Inc. Submits New Drug Application to Fda for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva stock rises on filing for FDA approval of schizophrenia therapy

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Insufficient new directors

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Price target decreased to US$6.67

Minerva Neurosciences, Inc. Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Price target increased to US$8.33

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Consensus revenue estimates fall to US$400.0k

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell 3000E Growth Index

Investor sentiment improved over the past week

Consensus forecasts updated

Minerva Neurosciences, Inc. Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Investor sentiment deteriorated over the past week

Analysts update estimates

Earnings beat expectations, revenue disappoints

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. to Report Q4, 2020 Results on Mar 08, 2021

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Bernstein Liebhard LLP Reminds Investors in SPLK, NAK, and NERV of Filing Deadlines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Minerva Neurosciences, Inc

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

New 90-day low: US$2.58

Block & Leviton LLP Announces That It Has Filed A Lawsuit Against Minerva Neurosciences, Inc. for Securities Fraud

A Potential Trade Arises On Minerva

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

New 90-day high: US$3.59

Earnings miss expectations

Minerva Neurosciences EPS beats by $0.03

Minerva Neurosciences, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day low - US$3.21

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell Microcap Value Index

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter